Next Article in Journal
Vaccines against Genital Herpes: Where Are We?
Next Article in Special Issue
Antiretroviral Therapy Interruption (ATI) in HIV-1 Infected Patients Participating in Therapeutic Vaccine Trials: Surrogate Markers of Virological Response
Previous Article in Journal
Expression of Concern: Artigas-Jerónimo et al. A Novel Combined Scientific and Artistic Approach for the Advanced Characterization of Interactomes: The Akirin/Subolesin Model. Vaccines 2020, 8, 77
Previous Article in Special Issue
Characterization of Physicians That Might Be Reluctant to Propose HIV Cure-Related Clinical Trials with Treatment Interruption to Their Patients? The ANRS-APSEC Study
Open AccessReview

The Potential of Immune Modulation in Therapeutic HIV-1 Vaccination

by 1,2,3,4,*, 1,3, 1,3, 1,2,3,5 and 1,2,3
1
Inserm, U955, Equipe 16, 94000 Créteil, France
2
Faculté de médecine, Université Paris Est, 94000 Créteil, France
3
Vaccine Research Institute (VRI), 94000 Créteil, France
4
INSERM U955 Equipe 16, Université Paris-Est Créteil, Vaccine Research Institute (VRI), 51, Avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France
5
AP-HP Hôpital H. Mondor—A. Chenevier, Service d’Immunologie clinique et maladies infectieuses, 94010 Créteil, France
*
Author to whom correspondence should be addressed.
Vaccines 2020, 8(3), 419; https://doi.org/10.3390/vaccines8030419
Received: 30 June 2020 / Revised: 22 July 2020 / Accepted: 23 July 2020 / Published: 27 July 2020
(This article belongs to the Special Issue Therapeutic Vaccination of HIV-infected Patients)
We discuss here some of the key immunological elements that are at the crossroads and need to be combined to develop a potent therapeutic HIV-1 vaccine. Therapeutic vaccines have been commonly used to enhance and/or recall pre-existing HIV-1-specific cell-mediated immune responses aiming to suppress virus replication. The current success of immune checkpoint blockers in cancer therapy renders them very attractive to use in HIV-1 infected individuals with the objective to preserve the function of HIV-1-specific T cells from exhaustion and presumably target the persistent cellular reservoir. The major latest advances in our understanding of the mechanisms responsible for virus reactivation during therapy-suppressed individuals provide the scientific basis for future combinatorial therapeutic vaccine development. View Full-Text
Keywords: cytokines; immune checkpoint blockers; combinatorial intervention; HIV-1; therapeutic vaccine cytokines; immune checkpoint blockers; combinatorial intervention; HIV-1; therapeutic vaccine
Show Figures

Figure 1

MDPI and ACS Style

Seddiki, N.; Picard, F.; Dupaty, L.; Lévy, Y.; Godot, V. The Potential of Immune Modulation in Therapeutic HIV-1 Vaccination. Vaccines 2020, 8, 419. https://doi.org/10.3390/vaccines8030419

AMA Style

Seddiki N, Picard F, Dupaty L, Lévy Y, Godot V. The Potential of Immune Modulation in Therapeutic HIV-1 Vaccination. Vaccines. 2020; 8(3):419. https://doi.org/10.3390/vaccines8030419

Chicago/Turabian Style

Seddiki, Nabila; Picard, Florence; Dupaty, Léa; Lévy, Yves; Godot, Véronique. 2020. "The Potential of Immune Modulation in Therapeutic HIV-1 Vaccination" Vaccines 8, no. 3: 419. https://doi.org/10.3390/vaccines8030419

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop